So, Advaxis (ADXS). If you follow me, you know it's one of the few stocks I write about that I actually own. So I'll have that disclaimer out of the way immediately.
In 2017, ADXS has gone through its first taste of validation with the presentation of GOG-0265 results back in March, but then it began a slow crawl down, punctuated by several rapid declines in stock price to new 52-week lows over the past 3 months.
ADXS data by YCharts
If you had asked me in March if the $3 area (corresponding to a market cap hovering around $150 million) was fathomable, I would have laughed you out of the room. As of their last quarterly filing, ADXS holds assets near $100 million.
